NHD Global
Antimicrobial peptide research · Human cathelicidin
Scientific Product Dossier
LL-37 is a peptide involved in the body’s early defense against microbes. Laboratory research examines bacterial growth, biofilms and signals involved in cell movement. These are separate measurements: an effect on a biofilm is not automatically the same as killing bacteria. Results also depend on the test medium and organism. This page explains the research and helps you check the catalog identity, selected variant and information needed for a research enquiry.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Reported EC50 values were 1.3–3.6 µg/mL across tested Pseudomonas and Staphylococcus strains.
Expression and direct-inactivation laboratory work; no patient administration.
Read the primary studyFDA identifies immunogenicity/characterization concerns plus nonclinical male-reproduction and protumorigenic findings.
These concerns require narrower public claims.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Gordon YJ, et al. Current Eye Research. 2005. PMID 16020269.
View primary recordU.S. FDA current LL-37 summary.
View primary recordThird-party publications selected for direct relevance.
Gordon YJ, et al. Current Eye Research. 2005. PMID 16020269.
U.S. FDA. Current compounding safety-information page.
Concise answers for researchers comparing identity, evidence and catalog variants.
In lab studies, LL-37 killed several Pseudomonas and Staphylococcus strains and reduced HSV-1 and adenovirus levels. It is also naturally made by cells on the eye surface, supporting its role in first-line defense. These findings help explain how human surfaces defend against microbes, but they do not show that LL-37 treats infections in people.
The antibacterial and antiviral effects come from laboratory experiments, not from people. Lab activity can point to promising mechanisms but cannot predict safe exposure or clinical benefit. The FDA has noted insufficient human safety data and nonclinical reproductive and tumor-related concerns. These limits are central to interpreting LL-37 research.
No. The cited ocular study measured expression and antimicrobial activity in laboratory assays.
No. Endogenous biology and exogenous exposure are different evidence questions.
Family-level identifiers organize the catalog. Confirm the supplied form, identity and release criteria using the applicable product specification and ask which lot records are available.
Tell us which records your project requires. Availability and scope must be confirmed for the selected material. Published papers are not batch certificates, and this page does not confirm that a lot-specific COA is available.
Request the storage conditions for the exact supplied form and selected variant. A temperature stated for another supplier or a clinical drug preparation is not a verified storage specification for NHD catalog material.
No. Check the organism, growth medium, exposure time, concentration basis and measured endpoint. The same peptide can be evaluated under different conditions. Compare the methods before attributing different results to the material.
Send the exact product name, selected catalog variant, required quantity, destination and documents needed for the project. Specify whether the amount refers to powder mass or measured peptide content. Availability, price, lead time and document scope require confirmation.
No. A paper describes the material and methods used in that study. It does not establish the identity, purity or content of a different supplied lot. Ask which records actually apply to the requested material; do not assume a COA is available.
Knowledge center
Owned educational content connected to this family.
A frequently cited LL-37 paper examined expression in human ocular-surface cells and antimicrobial activity in laboratory assays. It did not administer LL-37 as a…
Updated October 1, 2026
“LL-37” can refer to an endogenous human defense peptide, a synthetic assay reagent or an engineered biological delivery system. Results from one of those…
Updated October 1, 2026
A peptide can reduce biofilm formation without stopping bacterial growth at the same concentration. The LL-37 study illustrates that distinction. Understanding what each test…
Updated October 9, 2026
A production estimate is useful only when its starting point, ending point and conditions are clear. Use this milestone sheet to separate production, analysis,…
Updated October 9, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: 375 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
